LEBWOHL, M.; BACHELEZ, H. .; GORDON, K.; WU, T.; CHEN, M.; KAPLAN, B.; PAPP, K. Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s258, 2023. DOI: 10.25251/skin.7.supp.258. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2428. Acesso em: 3 jul. 2024.